Prevalence of Steatosis and Steatohepatitis in Patients Undergoing Bariatric Surgery; a Biopsy-based Study

NCT ID: NCT06499675

Last Updated: 2024-07-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

272 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-01

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the prevalence of steatosis, steatohepatitis, and their associated risk factors in obese patients undergoing bariatric surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective single-center biopsy-based study was conducted on 162 sleeve gastrectomy patients. Patient characteristics, including age, sex, diabetes mellitus (DM) status, body mass index (BMI), liver function tests, lipogram, homeostatic model assessment of insulin resistance (HOMA-IR), and steatosis were also assessed using controlled attenuation parameter (CAP), and intra operative liver biopsies were obtained. , The presence of steatosis and steatohepatitis were histologically assessed by two expert pathologists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Obesity, Morbid Bariatric Surgery Candidate Steatosis of Liver Steatohepatitis, Nonalcoholic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

obese patients

sleeve gastrectomy

Intervention Type PROCEDURE

sleeve gastrectomy / bariatric surgery

Liver Biopsy

Intervention Type PROCEDURE

intraoperative liver biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sleeve gastrectomy

sleeve gastrectomy / bariatric surgery

Intervention Type PROCEDURE

Liver Biopsy

intraoperative liver biopsy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing laparoscopic sleeve gastrectomy ≥18 years of age.
* Able to give written informed consent.
* Scheduled, independently from this study, to have a liver biopsy (LB).
* Negative for hepatitis B surface antigen, anti-hepatitis C virus, hepatitis C virus-RNA, and hepatitis B virus DNA.
* BMI greater than or equal to 40, or BMI greater than or equal to 35 with at least one obesity-related comorbid condition (including type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea (OSA), GERD, asthma, venous stasis disease, severe osteoarthritis, or considerably impaired quality of life).
* Unsuccessful nonoperative weight loss attempts.
* Mental health clearance.
* Recent updates have included patients with a BMI of 30-35 with uncontrollable type 2 diabetes or metabolic syndrome as an indication for a laparoscopic sleeve gastrectomy.

Exclusion Criteria

* Patients with ascites.
* Pregnant women.
* Patients with any active implantable medical device (such as pacemaker or defibrillator).
* Patients who had undergone liver transplantation.
* Patients with cardiac failure and significant valvular disease.
* Patients with hemochromatosis.
* Patients who refused to undergo liver biopsy or blood tests.
* Patients with alcohol consumption above recommended limits (\>14 units/week for women and \>21 units/week for men; 1 unit = 8 g of ethanol).
* Patients with a confirmed diagnosis of active malignancy or another terminal disease.
* Patients participating in another clinical trial within the preceding 30 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Egyptian Liver Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Egyptian Liver Research Institute and Hospital (ELRIAH)

Sherbin, Dakahlia Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Steatosis2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bariatric Surgery on NASH
NCT04043585 COMPLETED
Bariatric Surgery for Obesity
NCT06901440 NOT_YET_RECRUITING
Bariatric Endoscopy and NAFLD
NCT04895943 ACTIVE_NOT_RECRUITING
Bariatric Endoscopy and NAFLD
NCT04669470 UNKNOWN NA